Entendiendo La Eficacia de Covi19
Entendiendo La Eficacia de Covi19
Vaccine efficacy in high-risk groups and reduced viral shedding are important for protection
The elderly and people with comorbidities are at greatest risk uncertainty about true effects in high-risk subgroups. This
of severe coronavirus disease 2019 (COVID-19). A safe and ef- uncertainty would be greater in interim analyses that are
fective vaccine could help to protect these groups in two dis- based on the number of events across the whole trial popula-
tinct ways: direct protection, where high-risk groups are tion and may be exacerbated if high-risk participants are
vaccinated to prevent disease, and indirect protection, where more cautious and have lower exposure to infection, reducing
First release: 21 October 2020 www.sciencemag.org (Page numbers not final at time of first release) 1
individually randomized Pragmatic Assessment of Influenza viral testing, irrespective of symptoms, to capture partici-
Vaccine Effectiveness in the DoD (PAIVED) trial, which as- pants during their period of acute infectiousness. The Oxford-
sesses the relative merits of three licensed influenza vaccines AstraZeneca vaccine trial is testing participants in the United
(NCT03734237). Kingdom for virus weekly regardless of symptoms, but not in
Another approach to amass evidence on subgroup-specific other trials for which protocols have been released. Even
efficacy is postapproval observational studies. This includes weekly testing will not give detailed information about the
active surveillance of high-priority cohorts from, for example, effect of the vaccine on viral shedding, and the relationship
nursing homes or assisted living facilities, as has been done between viral loads and infectiousness is unknown; nonethe-
for influenza. This also includes test-negative designs, which less, this approach is likely to provide some evidence if viral
are routinely used to assess vaccine effectiveness (4). Symp- loads are on average lower among vaccinated people. Human
tomatic individuals that test negative for severe acute respir- challenge vaccine studies, in which individuals in a random-
atory syndrome coronavirus 2 (SARS-CoV-2) function as ized controlled trial are deliberately exposed to the virus,
controls for test-positive cases, and their vaccination status is could generate high-quality data on the effect of vaccines on
compared, adjusting for selected confounders. Test-negative viral shedding (9).
First release: 21 October 2020 www.sciencemag.org (Page numbers not final at time of first release) 2
may be optimal for reducing mortality even if the vaccine is
somewhat less effective in these groups (2). But if a vaccine
offers little to no protection in high-risk groups yet is able to
reduce infection or infectiousness in younger adults, an indi-
rect strategy could be preferred as vaccine supplies become
large enough (1, 2). A worst-case scenario for an effective vac-
cine is one that reduces disease in younger adults but pro-
vides neither direct nor indirect protection to high-risk
groups, leaving the most vulnerable at risk. Knowing these
vaccine characteristics is important when evaluating the rel-
ative merits of other products. Fortunately, there are many
vaccine candidates in development that use a mixture of in-
novative and existing technologies. Although vaccines may
vary in their characteristics, having reliable evidence on di-
First release: 21 October 2020 www.sciencemag.org (Page numbers not final at time of first release) 3
Downloaded from http://science.sciencemag.org/ on October 21, 2020
First release: 21 October 2020 www.sciencemag.org (Page numbers not final at time of first release) 4
Understanding COVID-19 vaccine efficacy
Marc Lipsitch and Natalie E. Dean
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of
Science, 1200 New York Avenue NW, Washington, DC 20005. The title Science is a registered trademark of AAAS.
Copyright © 2020, American Association for the Advancement of Science